Endovascular Approach to Glomus Jugulare Tumors

Damian Kocur1, Wojciech Ślusarczyk2, Nikodem Przybyłko3, Mariusz Hofman3, Tomasz Jamróz3, Krzysztof Suszyński4, Jan Baron5, Stanisław Kwiek3

1 Department of Neurosurgery, prof. Gibiński Central Clinical Hospital, Katowice, Poland
2 Department of Physiology, Medical University of Silesia, School of Medicine in Katowice, Katowice, Poland
3 Department of Neurosurgery, Medical University of Silesia, School of Medicine in Katowice, Katowice, Poland
4 Department of Sports Medicine and Physiology of Physical Effort, Medical University of Silesia, School of Medicine in Katowice, Katowice, Poland
5 Department of Radiology and Nuclear Medicine, Medical University of Silesia, School of Medicine in Katowice, Katowice, Poland

Author’s address: Damian Kocur, Department of Neurosurgery, prof. Gibiński Central Clinical Hospital, Medyków 14 Str., 40-001 Katowice, Poland, e-mail: damkocur@gmail.com

Summary

Background: Paragangliomas are benign neuroendocrine tumors derived from the glomus cells of the vegetative nervous system. Typically, they are located in the region of the jugular bulb and middle ear. The optimal management is controversial and can include surgical excision, stereotactic radiosurgery and embolization.

Case Report: We report the endovascular approach to three patients harboring glomus jugulare paragangliomas. In all cases incomplete occlusion of the lesions was achieved and recanalization in the follow-up period was revealed. Two patients presented no clinical improvement and the remaining one experienced a transient withdrawal of tinnitus.

Conclusions: It is technically difficult to achieve complete obliteration of glomus jugulare tumors with the use of embolization and the subtotal occlusion poses a high risk of revascularization and is not beneficial in terms of alleviating clinical symptoms.

MeSH Keywords: Embolization, Therapeutic • Glomus Jugulare • Glomus Jugulare Tumor • Paraganglioma

PDF file: http://www.polradiol.com/abstract/index/idArt/901141

Background

Glomus tumors, also known as paragangliomas or chemodectomas, are benign neuroendocrine tumors derived from the glomus cells of the vegetative nervous system [1,2]. They can be found in a wide range of locations in the human body [3]. One of the most typical location is the temporal bone in the region of the jugular bulb and middle ear. These types of paragangliomas are termed glomus jugulare or jugulotympanic tumors (GJTs) and are the most common tumors that develop in the jugular foramen [4]. Glomus tumors are rare, with an incidence of about 1 per 1 million and a marked predisposition in women [1,3,5]. The majority of these tumors are slow-growing with a clinical manifestation in the sixth to seventh decade of life [1,3]. The typical expansive and locally destructive growth pattern of glomus jugulare tumors leads to cranial nerve damage with related symptoms (facial palsy, pulsatile tinnitus, hearing loss, difficulty in swallowing and loss of voice) and in larger tumors brainstem compression can be seen [1–3,5]. Despite the fact that these tumors are an urgent and life-threatening condition, only in exceptional situations do they have a negative impact on the quality of life in the mid- or long-term [3]. While clinical signs are essential as an initial clue to a mass located in the temporaljugular area, a clinical diagnosis of GJTs based of imaging studies may be established with a high probability [3,6]. Computed tomography (CT), magnetic resonance (MR), time of flight magnetic resonance angiography (TOF MR) and digital subtraction angiography (DSA) are commonly applied. These infiltrative tumors follow the path of least resistance, and in CT scans expansion and erosion of the temporal bone is depicted with a characteristic
A 66-year-old woman presented with a left-sided jugulo-tympanic glomus tumor. She had been complaining of progressive left-sided peripheral paresis of the facial nerve, reaching the 5th degree on the House-Brackmann scale, and left-sided hearing deficits. After selective angiography, a partial tumor embolization through 3 feeding arteries was performed with the use of acrylic glue, "Glubran 2" (GEM Srl, Viareggio, Italy) and contrast agent "Lipiodol" (Glubran 2: Lipiodol 1: 1). Further complete embolization was not feasible because of technically challenging catheterization of the small vessels supplying the lesion. The clinical status did not improve. A follow-up angiogram taken one month later showed revascularization of the lesion (Figure 2). The patient did not agree to further treatment.

Case 3

A 45-year-old man was diagnosed with a left jugulo-tympanic paraganglioma. In addition, he had been treated for multiple sclerosis for several years. Over 10 years, the patient had been complaining of left-sided hearing deficits progressing gradually to deafness. Additional neurological symptoms included spasticity of upper and lower limbs, increased deep tendon reflexes, monoparesis of the right lower limb (3rd degree), hypoesthesia (pain, temperature) of the left upper and lower limbs. Following DSA, a two-staged partial embolization was performed via branches of the ECA with the application of micromolecules of PVA (150–255 μm) and PVA 100. (Figure 3A, 3B). A follow-up DSA performed 13 months later revealed an enlargement of the previously revealed tangle of vessels (Figure 3C). The third stage of embolization with micromolecules of PVA (300 μm) performed via 4 feeding branches also resulted in a subtotal occlusion. The navigation through the smallest arterial feeders was not feasible which resulted in only partial obliteration of the vascular channels of the paraganglioma. The clinical status did not improve. The patient was referred for stereotactic radiotherapy.

Discussion

An optimal management of paragangliomas has not been unequivocally established and the available armamentarium includes surgery, stereotactic radiosurgery and endovascular therapy [1,3]. In addition, observation of the clinical status of patients and radiological tumor follow-up is also an option [1]. Although the natural course of GJTs has not been ultimately recognized, these tumors are likely to grow with a reported tumor doubling time longer than 4.2 years [1,6]. If there is no evolution of clinical symptoms, patients should be followed up with MR imaging up to every two years [6]. Conservative treatment of paragangliomas, however, remains controversial as early surgical resection of smaller lesions is associated with a decreased morbidity and a higher likelihood of radical resection [6]. Moreover, an observational strategy may be inappropriate in young patients with a long life expectancy [8]. Surgical tumor excision results in a 90% control rate of resected lesions, and since tumor shrinkage is not guaranteed following radiotherapy, surgery may be inevitable in case of tumor mass effect and related intracranial hypertension, hydrocephalus or brainstem compression [1,3]. However, neurological consequences of surgical resections are significant and mainly include persistent cranial nerve deficits;
this relates especially to jugular or jugulotympanic paragangliomas [2,3,8]. Even in experienced centers, the results are not satisfactory and the overall mortality rate ranges from 1.2% to 6.4% [3].

Stereotactic radiosurgery may be applied as the treatment of choice [2,3,6,9]. In paragangliomas, this method results in lower morbidity than surgery with a possibility of clinical improvement [3]. It provides a good long-term tumor control, with 61% of the tumors stable in size [3]. Recent studies have shown a long-term neurological improvement in 42% of patients and aggravation of clinical symptoms in 4% of patients treated with stereotactic radiosurgery [9–11].

As far as endovascular therapy is concerned, it is confined to preparation for surgery and palliative applications, but it
is not curative [3,6,12]. As regards preoperative embolization through feeding vessels, its role is to decrease blood loss during surgical procedures and to help perform resections in a more secure manner [12–15]. In case of head and neck paragangliomas, both transarterial embolization with polyvinyl alcohol (PVA) particles and direct percutaneous embolization with n-butyl cyanoacrylate (NBCA) or ethylene vinyl alcohol polymer (Onyx) are used [16]. Either way, the procedure of presurgical adjuvant endovascular embolization is safe and effective, and the application of this form of therapy followed by surgical excision of paragangliomas is widely accepted [3,8,17]. In the literature, symptomatic treatment of paragangliomas is reported to be an alternative [3,6]. Paragangliomas are well-vascularized tumors and as a palliative treatment endovascular occlusion of tumor arterial supply is reported to have a positive impact on clinical symptoms including vertigo and tinnitus [3,13,17]. However, because of the multitude of arterial feeders and pedicles originating from eloquent branches, a total embolization is difficult to achieve [18], which is confirmed by the current study. Although according to the available reports the therapeutic role of endovascular procedures in the palliative treatment of glomus jugulare tumors may demonstrate a certain clinical effectiveness and radiological stabilization [8,19,20], embolization as a sole treatment for paragangliomas is not advised [2,3,13]. The data published so far are sparse, with various embolic agents, including autologous muscle, Spongostan, PVA particles, coils and glue [18]. Our results are likely to indicate that a complete embolization of GJTs through the transarterial route is technically challenging and a subtotal embolotherapy has a limited impact on clinical symptoms. Moreover, an endovascular occlusion of tumor-feeding vessels is characterized by a high degree of recurrence. One of the reasons may be the application of older intravascular embolization agents such as PVE and acrylic glue. The recent data

Figure 2. Axial (A) and coronal (B) T1+C magnetic resonance imaging sequences demonstrate a left-sided, homogeneously enhancing glomus jugulare tumor with a maximal diameter of 2.7 cm.

Figure 3. Left external carotid injection (A) presents a jugulo-tympanic paraganglioma tumoral blush. Two-staged embolization was performed with a subtotal effect of vascular occlusion (B). A control angiogram taken 13 months later revealed significant tumor revascularization (C).
concerning a new embolic agent Onyx are promising [18]. Michelozzi et al. reported a series of 10 patients with jugular/jugulotympanic paragangliomas who underwent Onyx embolization alone, and 7 tumors were stable in size during a mean follow-up of 45.7 months [8]. As far as the stabilization of a tumor size is concerned, it seems questionable if there is an advantage of such management over no treatment. Nonetheless, the regression of preoperative clinical symptoms was achieved in eight cases of the above-mentioned ten patients, and there were two recurrences [8]. It should be mentioned, however, that the authors presented patients with cranial nerve deficits that appeared following endovascular treatment of jugulo-tympanic paragangliomas [8]. This shows that endovascular intervention in jugular/tymanojugular paragangliomas carries a certain risk of complications such as cerebellar/brainstem infarction resulting from embolic material embolism and cranial nerve palsies, as a consequence of tumor swelling and nerve compression or embolic ischemia of the vasa nervorum [3,8].

Conclusions

Endovascular treatment of glomus jugulare tumors is associated with technical difficulties in achieving complete occlusion of the lesions. Subtotal embolization is characterized by a high degree of revascularization and appears not to be beneficial in terms of alleviating clinical symptoms.

References:

5. Greenberg MS, Greenberg MS (eds.): Handbook of neurosurgery. 7th ed. Tampa, FL, Greenberg Graphics, 2010